Navigation Links
Zevalin Consolidation in Patients With Complete Remission After Induction Therapy Results in Durable Remission of More Than 67 Months
Date:12/8/2008

apy called radioimmunotherapy and is indicated as part of the Zevalin therapeutic regimen for treatment of relapsed or refractory, low-grade or follicular B-cell non- Hodgkin's lymphoma, including patients with rituximab refractory follicular NHL. Zevalin is also indicated, under accelerated approval, for the treatment of relapsed or refractory, rituximab-naive, low-grade and follicular NHL based on studies using a surrogate endpoint of overall response rate. It was approved by the FDA in February of 2002 as the first radioimmunotherapeutic agent for the treatment of NHL.

Rare deaths associated with an infusion reaction symptom complex have occurred within 24 hours of rituximab (Rituxan(R)) infusions. Yttrium-90 Zevalin administration results in severe and prolonged cytopenias in most patients. Severe cutaneous and mucocutaneous reactions have been reported. The most serious adverse reactions of the Zevalin therapeutic regimen were primarily hematologic, including neutropenia, thrombocytopenia and anemia. Infusion-related toxicities were associated with pre-administration of rituximab. The risk of hematologic toxicity correlated with the degree of bone marrow involvement prior to Zevalin therapy. Myelodysplasia or acute myelogenous leukemia was observed in 2 percent of patients (8 to 34 months after treatment). Zevalin should only be used by health care professionals qualified by training and experience in the safe use of radionuclides.

Patients and healthcare professionals can visit http://www.zevalin.com for more information.

About Non-Hodgkin's Lymphoma

Non-Hodgkin's lymphoma (NHL) is caused by the abnormal proliferation of white blood cells and normally spreads through the lymphatic system, a system of vessels that drains fluid from the body. NHL can be broadly classified into two main forms -- aggressive NHL, a rapidly spreading acut
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Zevalin(R) Combined With High-Dose Chemotherapy and Autologous Stem-Cell Transplantation (ASCT) Produces High Overall Survival and Progression-Free Survival Rates in Patients With Relapsed Non-Hodgkins Lymphoma
2. Phase II Study of Zevalin(R) Consolidation Following Fludarabine and Mitoxantrone Chemotherapy Results in 100 Percent Complete Remission Rate and 89 Percent Three-Year Progression Free Survival in Patients with Previously Untreated Non-Follicular Indolent
3. Fludarabine, Mitoxantrone and Zevalin(R) Produces 96% Complete Remission Rate in First-Line Treatment of Patients with Follicular Non-Hodgkins Lymphoma
4. Sequential R-CHOP and Ibritumomab Tiuxetan (Zevalin(R)) Regimen Produces Impressive Survival Rates in High Risk Elderly Patients With Untreated Aggressive Diffuse Large B-cell Lymphoma
5. Cell Therapeutics, Inc. (CTI) to Hold Conference Call to Discuss Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data
6. CTI to Meet With the FDA to Discuss Filing of a Supplemental Biologics License Application for Zevalin(R)
7. Zevalin(R) Following Short-Course Chemotherapy with CHOP + Rituximab (CHOP-R) Doubles Complete Remission Rate in First-Line Treatment of Follicular Non- Hodgkins Lymphoma
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
10. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
11. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... 4, 2015  Intec Pharma Ltd. (the "Company") (NASDAQ: ... on developing drugs based on its proprietary Accordion Pill ... public offering in the United States ... price to the public of $6.00 per ordinary share, ... shares are being offered by the Company.  In addition, ...
(Date:8/4/2015)... Aug. 4, 2015 Concord Medical Services Holdings Limited ... hospital management solution provider and operator of the largest network ... , today announced it will release its financial results ... on August 17, 2015. Management will hold a ... 8:00 a.m. EDT on August 18, 2015 (8:00 p.m. in ...
(Date:8/4/2015)... , Aug. 4, 2015 BioElectronics ... over-the-counter ActiPatch® Musculoskeletal Pain Therapy medical devices, announced ... of its ActiPatch 7-day trial device has been ... Pain Management http://www.futuremedicine.com/doi/full/10.2217/PMT.15.35 .  More ... survey and submitted an assessment.  ...
Breaking Medicine Technology:Intec Pharma Ltd. Announces Pricing of U.S. Initial Public Offering 2Intec Pharma Ltd. Announces Pricing of U.S. Initial Public Offering 3Concord Medical to Report Second Quarter 2015 Financial Results on August 17, 2015 2BioElectronics' Landmark 5,000+ Chronic Pain Patient Study Published in Pain Management Medical Journal 2
(Date:8/4/2015)... , ... August 04, 2015 , ... ... which provides vascular, electrocardiogram (EKG), echocardiogram, and NCV testing, announced their collegiate ... successfully identifying previously undiagnosed cardiovascular abnormalities one program at a time. ...
(Date:8/4/2015)... ... ... Bayco Products, Inc. announces a new industrial-grade LED Dual-LightTM headlamp in a new, ... a flip-up face shield. The sleek contours of the new Nightstick NSP-4614B Low-Profile ... headlamp when raising or lowering their face shield or visor. The 4614 will be ...
(Date:8/4/2015)... ... August 04, 2015 , ... Worldwide Power ... Products is expanding its reach in Texas. Effective July 1st of this year, ... Texas generator division. With the North Texas acquisition, Worldwide Power Products (“WPP”) ...
(Date:8/4/2015)... (PRWEB) , ... August 04, 2015 , ... One of ... interviews to discuss his new book, The Pain Antidote , which provides strategies ... of Las Vegas Recovery Center’s Chronic Pain Treatment Program, wrote the book in conjunction ...
(Date:8/4/2015)... Yardley, Penn. (PRWEB) , ... August 04, 2015 , ... ... helping patients better understand certain health conditions, pictures and medical art can be essential. ... health care providers. , Krames Patient Education solutions have been used by physicians ...
Breaking Medicine News(10 mins):Health News:Colleges and High Schools Across the Country Are Joining the Wimbledon U Team Uncovering Unknown Cardiac Conditions and Promoting Heart Healthy Athletes 2Health News:Colleges and High Schools Across the Country Are Joining the Wimbledon U Team Uncovering Unknown Cardiac Conditions and Promoting Heart Healthy Athletes 3Health News:New Nightstick® NSP-4614B Dual-LightTM Headlamp fits more functionality into more places 2Health News:New Nightstick® NSP-4614B Dual-LightTM Headlamp fits more functionality into more places 3Health News:North Texas Acquisition Press Release 2Health News:Medical Expert's New Book Offers Help for Chronic Pain Sufferers 2Health News:Medical Expert's New Book Offers Help for Chronic Pain Sufferers 3Health News:StayWell Offers Instant Downloads, Licensing of Medical Art to Improve Patient Education 2Health News:StayWell Offers Instant Downloads, Licensing of Medical Art to Improve Patient Education 3
... of 50 years of publishing groundbreaking research, the June ... that highlight pivotal research and significant discoveries in the ... is available without charge from HFES., For over half ... to the safety and efficiency of systems, environments, tools, ...
... July 9, 2008 Led by Anna Catriona Phillips ... a hepatitis A vaccine in young healthy adults and also ... adults. , In the first study, participants consisted of ... hepatitis A vaccine during a morning session (10 am to ...
... Zimmer Holdings, Inc.,(NYSE and SWX: ZMH) announced today its ... broadcast live over the Internet on,Thursday, July 24, 2008, ... quarterly results will be made available at 7:00 a.m. ... webcast can be accessed via Zimmer,s Investor Relations,website at ...
... Wash. -- Many coaches inspire better performance by pressuring ... improve the performance of their analyses. In a simple ... that adding pressure early in their protocol squeezes four ... were really happy to see how well it worked," ...
... procedure keeps heart tissue alive, benefits other organs, study ... to CPR alone, adding extracorporeal life support doubles survival ... by researchers at the National Taiwan University Hospital. , ... artery/vein. The patient receives CPR until the start of ...
... connection , , WEDNESDAY, July 9 (HealthDay News) -- Being born ... cautious personality as an adult. , A study published in ... adults who were born at extremely low birth weights were ... counterparts who had been born at normal weights. , ...
Cached Medicine News:Health News:Human Factors Journal celebrates 50 years 2Health News:Pressured proteins: A little pressure in proteomics squeezes 4-hour step into a minute 2Health News:Pressured proteins: A little pressure in proteomics squeezes 4-hour step into a minute 3Health News:ELS Plus CPR Boosts Blood Flow After Cardiac Arrest 2Health News:Do Underweight Newborns Make for Shy Adults? 2
... Manager is the most ... critical care data management ... PDM is an ... to effortlessly manage all ...
... the wall-mounted organizer with a complete set of ... diameters. The Micro Nest makes it easier for ... cleaning task. These small instrument cleaning brushes from ... such as cannulas. ISI Micro Brushes are available ...
... Instra-Glide Target is the non-silicone lubricant ... , ,Instra-Glide Target lubricates sticky pivot points, ... The penetration straw allows you to lubricate ... and painted surfaces. Ideal for carts, hinges, ...
... Hemaway Original attacks dried blood, tissue, ... in hard to reach places such as ... reducing the need for scrubbing. Hemaway Original ... but gentle enough to be used everyday. ...
Medicine Products: